Global Medical Strategy Director (MD)

Today, Pfizer Oncology has an industry-leading portfolio of 25 approved innovative cancer medicines, including major therapies for metastatic breast cancer, prostate cancer, urothelial carcinoma and haemato-oncological malignancies. Pfizer's in-line portfolio is focused on four broad, key areas: breast cancer, genitourinary cancer, hematology and precision medicine, complemented by an extensive pipeline of over 50 programs in clinical development.

• The role primarily supports the Global Medical Strategy Lead in developing and executing medical deliverables for pipeline and in-line products as a part of the Clinical Trial Study Team, and other cross-functional Pfizer Oncology , Pfizer Research and Development (PRD) and International Medical Affairs -led teams; and reporting into the Medical Sub Team (MST) of the Global Product Team ( G P T ) as needed. This individual will be responsible, at the product/asset level, for the oversight of medical deliverables for one-or-more clinical stud ies or in-line products end - to - end .
  
• The incumbent will be a key interface for Pfizer Oncology with the rest of the business, they will work cross-functionally with Clinical Trial Study Teams and other cross-functional teams as needed , including with colleagues in Oncology Clinical Development, International Medical Affairs, Safety, Oncology Regulatory Strategy, Global Value and Access (and other functions as needed) and in both early and late development
  

ROLE RESPONSIBILITIES

• The role is responsible for being the p oint contact on medical topics for all members of the Clinical Trial Study team and other cross-functional teams as needed and support the interface into the MST as they advance key deliverables end to end, from study concept through study data read out and closure .
  
• Support lightspeed clinical trial execution through collaboration with C linical O perations, C linical D evelopment , Oncology Field Medical and International Medical Affairs on Key Opinion Leader ( KOL ) /Investigator identification and site education and support .
  
• Provide m edical, clinical landscape, and product expertise into Clinical Development Plans and trial designs .
  
• Establish deep connectivity with Clinical Trial Study teams to advance key deliverables end to end, from study concept through study data read out and closure .
  
• Leverage KOL network and insights to inform and adapt (in real time) R&D level programs and deliverables .
  
• Collaborate cross functionally with Oncology Medical colleagues and International Medical Affairs colleagues to prepare and drive scientific engagement plans to support trial awareness, site education, and recruitment initiatives.
  
• Build relationships with P rincipal I nvestigator s (PIs) /KOLs and other external R&D stakeholders to help gather medical insights that can influence clinical development and medical strategy .
  
• Collaborate with Oncology Medical colleagues and International Medical Affairs colleagues to co-develop integrated evidence plans with Pfizer US ( Medical Platforms) including :
  

• Capture, catalog, and triage prioritize m edical insights and unmet needs from regulators, trial PIs/KOLs, Patients, and other R&D stakeholders .
  
• Understand the needs of other health system stakeholders (e.g., HTAs, payers, providers )
  
• Identify appropriate research methods and prioritization of evidence generation activities for development related priorities (incl. R&D-facing RWE)
  

• Day to Day contact for Investigators leading Investigator Sponsored Research studies
  
• Work with Oncology Medical and International Medical Affairs to enable where appropriate , early patient access through sanctioned programs where there are significant delays in market availability, and urgent unmet need as identified . Assess implications of Pre-approval Access Programs on the clinical development plan and regulatory status. Provide required framework / guardrails for potential program conduct based on clinical trial experiences and available clinical evidence (e.g., inclusion/exclusion criteria, tools, etc.)
  
• Support e stablish ment of the S cientific C ommunications P latform (SCP) early in development based on target profile, clinical evidence, disease state / landscape, and aspirational label.
  

• Enrich the SCP (based on cross-functional input in the MST) with evolving evidence from clinical studies, the Clinical Development Plan and regulatory strategy to ensure teams use accurate , consistent language and referencing aligned with the overarching MST strategy .
  
• Ensure the medicine-level SCP is aligned to the broader tumor and/or modality scientific narrative .
  
• Support establishment of Publications Plan based on upcoming data readouts from R&D driven programs, including evidence / meta-analyses designed to address regulatory / safety topics .
  
• Based on input from Oncology Medical and International Medical Affairs (regarding for example, regional/local evidence generation and non-R&D RWE / HEOR studies), facilitate the creation of the holistic global Publications Plan for a medicine, to be approved at MST and endorsed by the G P T
  

• Work closely with CSTs during data readouts to determine key messages and publication content (aligned to overall publication strategy and Scientific Communications Platform) and work with Pfizer US (Medical Platforms) on execution. Ensure the Publications Plan is aligned with the Scientific Communications Platform
  
• Identify needs for global medical education and awareness raising during development (including target-awareness, disease state awareness and scientific leadership in a therapeutic platform (e.g., ADCs)) and fund delivery through Pfizer US (Medical Platforms) . Support c o-development of Global Medical Education strategy and functional Plans (e.g., symposia, CME program, etc.) at MST, with input from Oncology Medical and International Medical Affairs .
  
• Interpret Pfizer Oncology and G P T needs / priorities and areas of interest from the scientific community to provide R&D pipeline and in-line portfolio content to be presented in the medical congress exhibits reflecting those priorities .
  
• Provide R&D m edical expert input / perspective into development of access plan as required . For key strategy initiatives (i.e., global Brand Plans, Global Launch Plans, etc.) provide an R&D m edical expert input / perspective as a G P T ambassador .
  

BASIC QUALIFICATIONS

• MD or DO in a relat ed medical f ield with demonstrated experience and understanding of biopharmaceutical drug development.
  
• Oncology clinical development or Medical Affairs experience needed; relevant academic and clinical Oncology experience will be considered.
  
• 1 2 + years of progressive experience in global medical affairs and/or clinical development in a pharmaceutical or biotech organization if a master's degree is held (or 9 + if holding an advanced or clinical degree ) .
  
• Knowledge of the Oncology competitive landscape, stakeholder community and demonstrated deep expertise of their TA and medicines they are supporting.
  
• Excellent interpersonal and communication skills.Ability to think strategicallywith a collaborative mindset and a proven track record of working effectively in diverse teams involving complex multi-functional disciplines.
  

Location is hybrid - must be on site 2.5 days per week

#LI-PFE

Relocation assistance may be available based on business needs and/or eligibility.

Sunshine Act

Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.

EEO & Employment Eligibility

Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.

Medical

#LI-PFE